Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Cdiff Test to detect Clostridium difficile (C. difficile) ...
The cobas® Cdiff Test targets the toxin B gene found in toxigenic C. difficile strains directly in specimens from symptomatic patients. The test provides accurate information which assists clinicians ...
Roche ($RHHBY) got an FDA OK for its rapid test for Clostridium difficile, picking up another regulatory gold star as it broadens its offerings on its cobas 4800 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback